LONDON, UK AND PLANO, TX, February 6, 2020. Belluscura PLC, in conjunction with its exclusive research partner Separation Design Group, announced today the filing of a patent application covering novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems for treating patients suffering from acute respiratory distress syndrome (ARDS).
The latest patent application covers devices and systems for treating people suffering from ARDS including patients suffering from the recent coronavirus in Wuhan, China. The primary cause of death from respiratory viruses like the coronavirus and influenza, are the result of the fluids accumulating inside the alveoli (the tiny air sacs of the lungs) which ultimately leads to the failure of the transfer of oxygen to and carbon dioxide out of the blood. The current primary treatment for ARDS is oxygen therapy along with ventilator support.
In cases where oxygen therapy and ventilator support are not effective, extracorporeal membrane oxygenation (ECMO), which circulates a patient’s blood through an oxygenation membrane, has been used to remove carbon dioxide from and diffuse oxygen into a patient’s blood while giving a patient’s lungs a chance to recover. Belluscura and Separation Design are designing and developing next generation, cost-effective, portable ECMO technology to treat ARDS patients.
Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said: “We are very excited about our next generation oxygen technologies. With the launch this year of our first product, the X-PLOR™ portable oxygen concentrator, into the respiratory treatment field where over 250 million people suffer from chronic obstructive pulmonary disease (COPD), the third leading cause of death, it is critical that we continue to innovate into the ever-expanding oxygen therapy market”.
LUCYD Files Patent for Voice Control App for Smartglasses
Tekcapital Plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is pleased to announce that its wholly owned portfolio company Lucyd Ltd, the developer of smartglasses and an eShop for advanced eyewear, has filed a new patent and a trademark on its forthcoming Vyrb™ app.
Vyrb users will be able to activate a world of smartphone actions with their voice in just moments, including social media posting, with Vyrb's flexible and intuitive user experience. By using the app along with Lucyd Bluetooth® glasses, the user can spend less time looking at their phone, and keep more of their focus on the real world. This is especially pressing given the rise in pedestrian fatalities due to smartphone distraction1.
Lucyd is targeting release of the the app in December 2020.
Harrison Gross, CEO and Co-founder of Lucyd said: "We are thrilled to announce our development of Vyrb, an app that can truly improve the way we access and share information. The voice is the easiest and most natural medium we have to interface with others and our devices, and we believe Vyrb will be a significant improvement to voice assistants, adding value to the billions of them already in use," said Harrison Gross, CEO and Co-founder at Lucyd.
Dr Clifford Gross, Executive Chairman at Tekcapital, commented: "We are glad to see Lucyd continue its innovation in the smart eyewear industry with its novel Vyrb™ app. We believe their new app will increase the utility of Lucyd Bluetooth® glasses and wireless "hearables" like Airpods®. It may also improve the safety of pedestrians and cyclists by enabling them to use their voice to create and respond to Twitter® and Facebook® posts, while keeping their eyes on the road.